Ritter Pharmaceuticals, Inc. Completes Phase 2 Clinical Study of RP-G28 for the Treatment of Lactose Intolerance

LOS ANGELES, CA--(Marketwire - November 17, 2011) - Ritter Pharmaceuticals, Inc. (Ritter) announced today the last patient has completed treatment in its Phase 2 study for RP-G28, a first-in-class treatment for symptoms associated with lactose intolerance. This multicenter, randomized, double-blind, placebo-controlled, parallel group study evaluated the effectiveness, safety and tolerability of RP-G28 in subjects with symptoms associated with lactose intolerance.

The study aims to demonstrate a significant drug effect correlating microbial changes and patient reported symptom improvements. Novel microbiome sequencing and genetic analysis will identify the microbiota of lactose intolerant individuals and contribute to the understanding of changes in colonic microflora, specifically, the modification and colonization by bacteria which improve lactose fermentation in the colon.

RP-G28 has the potential to become the first prescription drug approved for the treatment of lactose intolerance, a debilitating disorder with long-term consequences. Lactose intolerance affects more than 80 million people in the United States and over 4 billion people worldwide.

"The completion of our Phase 2 study represents a major milestone for the company. The knowledge gained from this study is invaluable, as Ritter establishes a pathway to approval for RP-G28," said Andrew Ritter, president and chief executive officer of Ritter Pharmaceuticals. "We are optimistic about the results of our Phase 2 trial, and we look forward to sharing data from the study in the first quarter of 2012."

About Lactose Intolerance

Lactose intolerance is a common gastrointestinal disease affecting over 4 billion people worldwide. People with lactose intolerance have a low activity level of lactase, the enzyme responsible for breaking down human lactose, resulting in one or more of the cardinal symptoms; including abdominal pain, cramps, bloating, gas, and/or diarrhea following the ingestion of lactose-containing foods.

About RP-G28

RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance. Treatment with RP-G28 stimulates colonic growth and helps to colonize the colon with lactose-fermenting bacteria, which reduces lactose-derived gas production, and thereby mitigates the symptoms of lactose intolerance. RP-G28 stands out as the only therapeutic regimen impacting the natural history of the disease and alleviating the symptoms of lactose intolerance on a long-term basis.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem. Ritter Pharmaceuticals is rapidly establishing itself as the world's leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field.

RP-G28, Ritter's lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 4 billion people worldwide.

For more information contact:

Jennifer Williams
Cook Williams Communications, Inc.
Email Contact

Back to news